Broad Institute

JULY 29, 2025

Collaboration aims to reduce animal use in drug safety testing By Leah Eisenstadt July 29, 2025 Breadcrumb Home Collaboration aims to reduce animal use in drug safety testing OASIS consortium is evaluating omics tools in cells, including Cell Painting and transcriptomics, to predict liver toxicity of potential new medicines and agrochemicals. By Leah Eisenstadt July 29, 2025 Credit: Axiom Bio, via Cell Painting Gallery (CC0 License) Members of the OASIS Consortium are employing the Cell Painting

Animal Testing

Science Daily: Pharmacology News

JULY 29, 2025

Scientists at Kyoto University have developed a groundbreaking "lung-on-a-chip" that can mimic the distinct regions of human lungs—airways and alveoli—to study how viruses like COVID-19 affect them differently. Powered by isogenic induced pluripotent stem cells (iPSCs), the system offers a high-fidelity way to model personalized immune responses and test drug effectiveness.

Immune Response

Covalent Modifiers

JULY 28, 2025

Bing Zhao, Sha Xu, Shiqing Zhou, Xiangru Jiang, Ailin Jiang, Hongrui Lei, Xin Zhai Bioorganic Chemistry, 163, 2025, 108800, [link] [link] the past two decades, covalent inhibitors have undergone a remarkable resurgence in drug discovery. Currently, targeting non-catalytic cysteine residues with acrylamide and other α,β-unsaturated carbonyl compounds is a predominate strategy, especially in the protein kinase field.

Research

Drugs.com

JULY 31, 2025

THURSDAY, July 31, 2025 — There’s potentially exciting news from a trial conducted in monkeys: A single shot of gene therapy given to newborn monkeys appears to shield them from HIV, the virus that causes AIDS, for at least three.

Virus

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Drug Target Review

JULY 31, 2025

While antibodies have long been a cornerstone of biomedical research, innovation in recombinant DNA technology over the past few decades has redefined possibilities in drug discovery and development. The sequencing, engineering and expression strategies used to create some of today’s most promising therapeutic modalities are now transforming capabilities in basic research and setting a new standard for reliable, high-quality antibody tools.

Engineering

Alta Sciences

JULY 31, 2025

Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development pmjackson Thu, 07/31/2025 - 14:42 Laval, QC, Canada, July 31, 2025 — Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation (“VoxCell”), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a strategic collaboration aimed at enhancing preclinical research and accelerating the path from discovery to clinical trials.

Drug Development

Science Daily: Pharmacology News

JULY 26, 2025

A groundbreaking study has revealed that the mass administration of ivermectin—a drug once known for treating river blindness and scabies—can significantly reduce malaria transmission when used in conjunction with bed nets.

Drugs

Codon

JULY 28, 2025

A gene is the essential hereditary unit that passes traits from parents to offspring; a segment of DNA containing instructions for making a specific protein or molecule that performs a particular function in your body. And yet, despite being fundamental to our flourishing, genes can be broken. Researchers have identified nearly 10,000 monogenic diseases , or conditions caused by errors in a single gene.

Immune Response

Drug Target Review

JULY 30, 2025

Radioligand therapy (RLT) has emerged as a powerful modality in oncology, offering highly targeted delivery of radiation to cancer cells while sparing healthy tissues. Although RLT has already demonstrated success in certain haematological and prostate cancers, its application in solid tumours has historically faced a number of biological and technical challenges – from limited tissue penetration to off-target toxicity, particularly in organs like the kidneys.

Clinical Trials

Crown Bioscience

JULY 28, 2025

Antibody-drug conjugates (ADCs) are among the most exciting advances in target cancer therapy. They combine the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs to focus treatment on malignant cells while reducing damage to healthy cells.

Small Molecule

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Chemical Biology and Drug Design

JULY 29, 2025

A drug repurposing strategy was applied against M. abscessus, through a virtual screening of FDA approved drugs on salicylate synthase. Eleven potential ligands were found; among these, three were confirmed as potent inhibitors of the enzyme. ABSTRACT Non-tuberculous mycobacteria (NTM) are opportunistic pathogens that lead to severe, persistent infections, particularly in immunocompromised or vulnerable individuals.

FDA Approval

Science Daily: Pharmacology News

JULY 31, 2025

In an exciting breakthrough, researchers have identified cancer drugs that might reverse the effects of Alzheimer's disease in the brain. By analyzing gene expression in brain cells, they discovered that some FDA-approved cancer medications could reverse damage caused by Alzheimer's.

FDA Approval

Drug Patent Watch

JULY 30, 2025

"The $100 Billion Shift: How Smarter API Manufacturing is Redefining the Pharmaceutical Industry As the pharma landscape continues to evolve, one thing is clear: the traditional model of big pharma dominance is no longer sustainable. A seismic shift is underway, driven by the rise of smarter API (Active Pharmaceutical Ingredient) manufacturing.

Pharmaceuticals

Drug Target Review

JULY 28, 2025

When discussing how newer AI technologies like large language models (LLMs) could contribute to toxicity prediction, Hosseini-Gerami identified two key applications: 1. Improved scientist–data interaction: “Once we have all these datasets, have run these algorithms and have some outcomes and outputs, how can a scientist really engage with that information and use it to make a decision on what to do next?

Drugs

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Pharma Manufacturing

JULY 31, 2025

The South Korean manufacturer and exporter of biosimilars said it has been designated as the preferred bidder on a large-scale cGMP drug substance facility.

Biosimilars

H1 Blog

JULY 28, 2025

More Information, Same Enrollment Challenges In clinical trial feasibility, we face a counterintuitive reality: despite unprecedented access to healthcare professional data, identifying the right investigators and predicting enrollment success has become increasingly challenging. This paradox, highlighted in a recent Life Sciences DNA podcast featuring Ariel Katz, co-founder and CEO of H1, in conversation with Dr.

Clinical Trials

BioPharma Drive: Drug Pricing

JULY 29, 2025

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical tests and is building a manufacturing network in support.

Science Daily: Pharmacology News

JULY 30, 2025

A new global study reveals a striking post-pandemic surge in gut-brain disorders like IBS and functional dyspepsia. Researchers compared data from 2017 and 2023 and discovered sharp increases—IBS up 28% and dyspepsia nearly 44%. Those suffering from long COVID were especially vulnerable, reporting more anxiety, depression, and worse quality of life.

Research

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Drug Target Review

JULY 30, 2025

The journey of cell and gene therapies from preclinical discovery to clinical trials is complex and challenging, impacting every team member involved, from researchers in the lab to patients receiving treatment. As CGT trials require innovative and flexible solutions, the need for technology such as interactive response technology (IRT) has become crucial in streamlining trial workflows, ensuring data integrity, and maintaining regulatory compliance as therapies advance from preclinical stages.

Clinical Development

PPD

JULY 29, 2025

Biopharma and biotech industries are facing remarkable challenges as the cost of developing new drugs has surged dramatically and clinical trial timelines have extended significantly. For example, over the past decade, the average time required to complete a clinical trial has increased by approximately 20-30%. These elongated timelines are contributing to soaring costs, with the average cost of developing a new drug rising to approximately $2.6 billion (versus $1-1.5 billion just a decade ago).

Clinical Trials

Drug Patent Watch

JULY 28, 2025

Uncovering the Secret Formulas: How Drug Patents Reveal the Competition's Playbook As the pharmaceutical industry continues to evolve, companies are under increasing pressure to innovate and stay ahead of the curve. But what if the key to unlocking your competitors' strategies lies in plain sight – hidden in the complex web of drug patents? A new analysis from Drug Patent Watch reveals the surprising ways in which competitors are using patent data to inform their formulation strategies.

Drugs

BioPharma Drive: Drug Pricing

JULY 29, 2025

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five drugs that no longer fit its plans.

Drugs

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

LifeSciVC

JULY 31, 2025

By Gerry Harriman, CSO and co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC As scientists, we are accustomed to learning something new about targets (and the modulation thereof) that moves the field forward in some way. In reality, such a learning is often incremental and while important, may not be ground-breaking.

Small Molecule

Collaborative Drug

JULY 28, 2025

Skip to content Login Search { Products CDD Vault Why CDD Vault Core Functionality Registration Activity Visualization Assays Add-ons ELN Inventory Curves AI AI + Automation Solutions Applications Assay Data Management Macrocycle Protein Therapeutic CRISPR PROTAC Antibody Drug Conjugate Small Molecules & Mixtures Industries Biotech & Pharmaceutical CRO Academics Agritechnology Consortia & Collaborations Consumer Goods User Roles Research Scientist Operations/IT Legal/Regulatory Execu

Testimonials

Reprocell

AUGUST 1, 2025

From retinal repair to diabetes treatment, induced pluripotent stem cell (iPSC)-derived cell therapies are entering clinical trials with increasing numbers over the last few years since their first generation and characterization 18 years ago. One of the most overlooked perils in mammalian cultures in general and in iPSC-derived products in particular is the accumulation of culture-induced genetic variants —mutations that can silently compromise safety, efficacy, and subsequent regulatory approv

Therapies

addgene Blog

JULY 29, 2025

This blog post was written by Dr. Kutubuddin Molla, investigator at ICAR-Central National Rice Research Institute. When it comes to genome editing, CRISPR is a name that resonates with nearly every biologist, academic, and researcher. Among the most well-known CRISPR-associated nucleases are Cas9 and Cas12a, the heavyweights in the genome editing toolbox.

Research

BioPharma Drive: Drug Pricing

JULY 29, 2025

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support of newer drugs and R&D.

Marketing

Perficient: Drug Development

JULY 29, 2025

For years, AI in customer service has been synonymous with efficiency. Businesses leaned on AI agents to reduce costs, deflect calls, and automate routine tasks. These agents were designed to streamline operations, not necessarily delight customers. But a new chapter is quickly unfolding. We’re now entering the era of agentic AI with a new generation of intelligent systems that don’t just respond to commands but act with purpose, context, and autonomy.

Engineering

FDA Law Blog: Biosimilars

JULY 27, 2025

By John A. Gilbert & Karla L. Palmer & Larry K. Houck & Andrew J. Hull — Last week, DEA registrants and applicants with pending actions before DEA’s Office of Administrative Law Judges (OALJ) received an order from Chief Administrative Law Judge John J. Mulrooney, II, staying the hearing proceedings in those cases. In those orders, Chief Judge Mulrooney announced that he was retiring from the bench effective August 1, 2025, and that, in the absence of any other DEA ALJs, all proceed

Regulations

thought leadership

JULY 28, 2025

Pharmacovigilance is a global responsibility, and regulatory requirements may differ significantly depending on the region. One such region-specific requirement is the Periodic Adverse Drug Experience Report (PADER) , a post-marketing safety report mandated by the U.S. Food and Drug Administration (FDA). While many in the pharmaceutical industry may already be familiar with the Periodic Safety Update Report (PSUR) , which we previously covered on our website, understanding how PADER differs from

Marketing

Drug Target Review

JULY 29, 2025

Effective financial management is a cornerstone in the success of clinical trials, which are integral to the advancement of drug discovery. As the pharmaceutical and biotech industries continue to evolve, clinical trials become more complex, and the importance of robust financial oversight has never been clearer. Jennifer Kyle, Founder and CEO of Condor Software, has witnessed these challenges first-hand and developed a solution aimed at bridging the gap between financial management and clinical

Clinical Trials

BioPharma Drive: Drug Pricing

JULY 30, 2025

The abrupt exit of the former CBER director, who quickly made his mark at the agency with several high-profile and controversial decisions, raises questions about where the FDA is headed.

FDA